Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNA NASDAQ:CUR NASDAQ:GNMX NASDAQ:VICL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsCURNeuralstem$0.75-3.5%$1.06$1.10▼$13.78$1.58M1.81236,278 shs120,021 shsGNMXAevi Genomic Medicine$0.17$0.17$0.11▼$0.35$12.89M1.133.16 million shs2.95 million shsVICLVical$1.24$0.60▼$1.47$21.01M0.321.44 million shs35,024 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CURNeuralstem+2.63%+7.59%+16.33%+14.71%-82.55%GNMXAevi Genomic Medicine0.00%0.00%0.00%0.00%0.00%VICLVical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AN/AN/AN/AVICLVicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena Pharmaceuticals 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/AGNMXAevi Genomic Medicine 0.00N/AN/AN/AVICLVical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ACURNeuralstem$260K6.08N/AN/A$6.64 per share0.11GNMXAevi Genomic MedicineN/AN/AN/AN/A$0.12 per shareN/AVICLVical$1.62M0.00N/AN/A$1.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ACURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AGNMXAevi Genomic Medicine-$30.77M-$0.50N/A∞N/AN/A-898.31%-286.73%N/AVICLVical-$16.25M-$0.81N/AN/AN/A-1,002.10%-29.46%-27.85%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AGNMXAevi Genomic MedicineN/AN/AN/AN/AN/AVICLVicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58CURNeuralstemN/A2.532.53GNMXAevi Genomic MedicineN/A0.650.65VICLVicalN/A36.8436.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%CURNeuralstem38.30%GNMXAevi Genomic Medicine7.03%VICLVical29.06%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%CURNeuralstem5.38%GNMXAevi Genomic Medicine43.80%VICLVical4.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableCURNeuralstem62.10 millionN/ANot OptionableGNMXAevi Genomic Medicine1477.71 millionN/AOptionableVICLVical3022.84 millionN/ANot OptionableVICL, GNMX, ALNA, and CUR HeadlinesRecent News About These CompaniesMattr introduces VICAL Viewer to ease mDL adoption for relying partiesSeptember 11, 2024 | biometricupdate.comBVical Announces Review of Potential Strategic TransactionsAugust 17, 2024 | br.advfn.comVical Reports Third Quarter 2018 Financial and Operational ResultsAugust 17, 2024 | br.advfn.comFresh Tracks Therapeutics (FRTX) Earnings Dates & ReportsMay 26, 2024 | investing.comEvan Gershkovich’s sister was the quiet one. Now she’s his voice.March 29, 2024 | msn.comVideo: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s SongMarch 29, 2024 | ijr.comISong Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, moreMarch 29, 2024 | msn.comSong lyrics getting simpler, more repetitive, angry and self-obsessed – studyMarch 29, 2024 | theguardian.comBeyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’March 29, 2024 | msn.comBeyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist?March 29, 2024 | msn.comCreed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream teamMarch 28, 2024 | msn.comBBC stands by replacing singer with AI-generated voiceMarch 28, 2024 | msn.comSong Lyrics Really Are Getting Simpler and More Repetitive, Study FindsMarch 28, 2024 | scientificamerican.comSFunniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee'March 28, 2024 | msn.comKanye wife Bianca Censori’s voice heard for first time in newly resurfaced videoMarch 28, 2024 | nydailynews.comTop 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the listMarch 28, 2024 | tennessean.comTSong Lyrics Are Now More Repetitive and Simple, Study ConfirmsMarch 28, 2024 | msn.comKJP Declares Press Gaggle off the Record as Obama’s Voice Is HeardMarch 28, 2024 | ijr.comISong lyrics have become angrier since the 80s, study showsMarch 28, 2024 | msn.comBoston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgeryMarch 28, 2024 | baltimoresun.comBVICL, GNMX, ALNA, and CUR Company DescriptionsAllena Pharmaceuticals NASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Aevi Genomic Medicine NASDAQ:GNMXAevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.Vical NASDAQ:VICLVical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
